Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dennis Lanfear Insider Profile
4 Followers
Dennis Lanfear, Director at Insmed, holds 1.23M shares in Coherus Biosciences (Ticker: CHRS), holds 168.40K shares in Insmed (Ticker: INSM).
Profitable Transactions
4 out of 5 Profitable Transactions
Average Return
+7.50%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Dennis Lanfear holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Jun 08, 2021 - Jun 08, 2022
Return:+43.00%
The most profitable trade made by Dennis Lanfear
Dennis Lanfear's Trading History
Insmed
Jun 11, 2010
Director
Uninformative Buy
―
$11.86M
Coherus Biosciences
Jan 23, 2024
President & CEO, Director
Uninformative Sell
27.37K
$1.87M
List of latest transactions for each holding click on a transaction to see Dennis Lanfear's performance on stock
You May Also Like
Dennis Lanfear insider profile FAQ
What is the percentage of profitable transactions made by Dennis Lanfear?
The percentage of profitable transactions made by Dennis Lanfear is 80%.
What is the average return per transaction made by Dennis Lanfear?
The average return per transaction made by Dennis Lanfear is 7.50%.
What stocks does Dennis Lanfear hold?
Dennis Lanfear holds: INSM, CHRS stocks.
What was Dennis Lanfear’s latest transaction?
Dennis Lanfear latest transaction was an Uninformative Sell of $27.37K.
What was Dennis Lanfear's most profitable transaction?
Dennis Lanfear’s most profitable transaction was an Informative Sell of CHRS stock on June 8, 2021. The return on the trade was 43.00%.
What is Dennis Lanfear's role in Insmed?
Dennis Lanfear's role in Insmed is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.